

# Policy Modelling for COVID-19: Better Data for Better Decision-Making in LMICs



Anna Vassall, Professor of Health Economics, Director CHIL (Centre for Health Economics in London), London School of Hygiene and Tropical Medicine, Anna.Vassalll@lshtm.ac.uk



### Policy choice for pandemics

- Wide interdependent policy choice set (health provision, public health, social care, humanitarian action, social protection, sectoral and macroeconomic policy)
- Multiple objectives (health, productivity, poverty/equity, security)
- Short and long run trade-offs
- Substantial and rapid
- Sectoral allocations flexible (to an extent)
- Continuously evolving, scarce, and localised data (4 months data available)
- Shift from private to public decision (externalities)
- High risk (high uncertainty and consequence)

**REVIEW** 

When an emerging disease becomes endemic

## Critical research questions (1)

Understanding the balance between intervention, 'duration and peak', mortality, productivity/ poverty in LMICs.

- Epidemiology (co-morbidities and risk factors)
- Social contacts, households and mixing (8 LMICs)
- Health sector capacity short run elasticity/cost/opportunity cost (TB/HIV, Vaccination)(Beds, HR, supplies)
- Intervention effectiveness and compliance
- Extent and distribution of household costs and coping
- Sectoral impacts
- Macro-economic (fiscal and monetary capacity)
- Social protection systems (UNICEF mapping)
- Secondary impacts (food security, emergency relief efforts, gender based violence)

#### Epidemiology

Public and private 'system capacity' – Supply side

Behaviour – Demand side



# Critical questions (2)

- Optimal intervention design in LMICs
  - When should we start and exit social distancing?
  - How severe should it be, and in which groups? (Mitigation or suppression)
  - What testing/what forms of contact tracing/isolation/ quarantine are sufficient?
  - How best to shield the vulnerable?
  - Critical care/ protecting health care workers?
  - What forms of social protection?
  - New technologies
- Principles and processes
  - How do we balance costs and multiple consequences between populations? (Ethics/ process, VSL/J Value)
  - How to we ensure production and fair access to technologies required to address Covid -19 across countries? Role of development financing/ debt relief.



#### What models do we have?

- In principle, models can be used to make sense of these complex decisions; 3 sets of models:
  - Infectious disease modelling (IDM) with broad estimates of resource use
  - Micro-economic evaluation models, combining the above with costs, to generate estimates of sectoral efficiency, with a limited societal perspective, possibly with some assessment of equity
  - Macro-economic modelling, that may estimate both sectors, productivity and health impact (but rarely linked to dynamic disease models)
- To date initial IDM results, and macro-economic models
- HIC focussed



#### Some useful resources:

- Walker P et al. <a href="https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-03-26-COVID19-Report-12.pdf">https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-03-26-COVID19-Report-12.pdf</a>
- CMMID working group. <a href="https://cmmid.github.io/topics/covid19/control-measures/EPI-suspension.html">https://cmmid.github.io/topics/covid19/control-measures/EPI-suspension.html</a> <a href="https://cmmid.github.io/topics/covid19/covid19/current-patterns-transmission/reports/COVID10k\_Africa.pdf">https://cmmid.github.io/topics/covid19/severity/Global\_risk\_factors.html</a>
- Barasa E. <a href="https://www.medrxiv.org/content/10.1101/2020.04.08.20057984v1.full.pdf">https://www.medrxiv.org/content/10.1101/2020.04.08.20057984v1.full.pdf</a>
- Shlomai A et al. <a href="https://www.medrxiv.org/content/10.1101/2020.03.30.20047860v1">https://www.medrxiv.org/content/10.1101/2020.03.30.20047860v1</a>
- Wang Q. <a href="https://www.medrxiv.org/content/10.1101/2020.03.20.20039644v2.full.pdf">https://www.medrxiv.org/content/10.1101/2020.03.20.20039644v2.full.pdf</a>
- Karnon J. <a href="https://link.springer.com/article/10.1007/s40258-020-00581-w">https://link.springer.com/article/10.1007/s40258-020-00581-w</a>
- Greenstone et al. <a href="https://papers.ssrn.com/sol3/papers.cfm?abstract\_id=3561244">https://papers.ssrn.com/sol3/papers.cfm?abstract\_id=3561244</a>
- Coming soon
- https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/covid-19-reports/
- https://www.lshtm.ac.uk/research/centres-projects-groups/chil



### 3 months data, decades of health economics

- Process/ Principles/ Metrics
  - Adapt HTA/ evidence based deliberation/MCDA
  - Balancing value of life with opportunity cost/ societal perspective
  - Equity
  - DALYs and QALYs, VSL, catastrophic costs and poverty cases averted,
- Modelling:
  - IDM models group open source
  - Cross walk models
  - Local links
- Data/ analysis
  - Communicate data needs
  - Compilation/ review/ rapid health systems capacity and costs, cost of illness/behaviours, values
  - THANK YOU!

